ArriVent BioPharma Inc
AVBPHealthcare|Biotechnology|USA
$33.69
+0.02 (+0.06%)
Tangible Book
$7.15
Upcoming Data Readouts (3)
Oct 2028
Est. completion
P3NSCLC
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NCT07010419n=338
Feb 2029
Est. completion
P3Non-Small-Cell Lung Cancer
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997n=480
May 2029
Est. completion
P1Locally Advanced or Metastatic Solid Tumors
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657n=405
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2025
P3
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
NCT05607550Jun 2025
P1
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
NCT05364073